Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NQO2 | P16083 | 1/20 | 0.63 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | ACP3 | P15309 | 1/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | SLC18A2 | Q05940 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5609654 | 0.88 | NQO2 (0.58) | NQO2CA2MTNR1ACYP1A2CYP2C19 | |
| SCHEMBL18272621 | 0.84 | NQO2 (0.57) | NQO2CA2MTNR1ACYP1A2CYP2C19 | |
| SCHEMBL13911250 | 0.84 | NQO2 (0.57) | NQO2CA2MTNR1ACYP1A2CYP2C19 | |
| SCHEMBL497025 | 0.81 | NQO2 (0.54) | NQO2CA2MTNR1ACYP1A2CYP2C19 | |
| SCHEMBL31300446 | 0.81 | NQO2 (0.54) | NQO2CA2MTNR1ACYP1A2CYP2C19 | |
| SCHEMBL5513121 | 0.81 | CA2 (0.57) | NQO2CA2MTNR1ACYP1A2CYP2C19 | |
| SCHEMBL65445 | 0.81 | NQO2 (0.54) | NQO2CA2MTNR1ACYP1A2CYP2C19 | |
| SCHEMBL6511791 | 0.81 | NQO2 (0.54) | NQO2CA2MTNR1ACYP1A2CYP2C19 | |
| SCHEMBL31078221 | 0.81 | NQO2 (0.54) | NQO2CA2MTNR1ACYP1A2CYP2C19 | |
| SCHEMBL3245793 | 0.81 | NQO2 (0.57) | NQO2CA2MTNR1ACYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4559890-A1 | STABILIZED METHOD FOR 18F-LABELING | Trasis S.A. (BE) | 2025-05-28 | — | — | EP | disclosed |
| US-9856182-B2 | Radiofluorination method | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2018-01-02 | — | — | US | disclosed |
| EP-2880005-B1 | RADIOFLUORINATION METHOD | UNIV DENMARK TECH DTU (DK) | 2016-05-25 | — | — | EP | disclosed |
| US-20150299066-A1 | RADIOFLUORINATION METHOD | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2015-10-22 | — | — | US | disclosed |
| EP-2880005-A1 | RADIOFLUORINATION METHOD | Technical University of Denmark (DK) | 2015-06-10 | — | — | EP | disclosed |
| US-20140086936-A1 | MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS | SOCPRA Sciences Sante et Humaines S.E.C. (CA) | 2014-03-27 | — | — | US | disclosed |
| WO-2014020035-A1 | RADIOFLUORINATION METHOD | TECHNICAL UNIVERSITY OF DENMARK (DK) | 2014-02-06 | — | — | WO | disclosed |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2012-10-25 | — | — | US | disclosed |
| US-7919508-B2 | 3-piperidinylisochroman-5-ols as dopamine agonists | AVENTIS PHARMACEUTICALS INC. (US) | 2011-04-05 | — | — | US | disclosed |
| EP-1749001-B1 | 3-PIPERIDINYLISOCHROMAN-5-OLS AS DOPAMINE AGONISTS | AVENTIS PHARMA INC (US) | 2010-03-03 | — | — | EP | disclosed |
| EP-1695716-A2 | Medicinal compositions containing diuretics and insulin sensitizers | Sankyo Company, Limited (JP) | 2006-08-30 | — | — | EP | disclosed |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2005-12-29 | — | — | US | disclosed |
| US-6858603-B2 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-01 | — | — | US | disclosed |
| EP-1354602-A1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | Sankyo Company, Limited (JP) | 2003-10-22 | — | — | EP | disclosed |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | AVENTIS PHARMA S.A. (FR) | 2003-08-28 | — | — | US | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | NQO2 876/4885CA2 217/4885MTNR1A 886/4885 |
| US-20120270838-A1 | SPIROIMIDAZOLONE DERIVATIVE | WNK3, REN, SGK3 | NQO2 335/4885CA2 921/4885MTNR1A 967/4885 |
| US-20150299066-A1 | RADIOFLUORINATION METHOD | PFAS, PHOSPHO1, ARFGEF1 | NQO2 2875/4885CA2 3009/4885MTNR1A 4878/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | NQO2 876/4885CA2 217/4885MTNR1A 886/4885 |
| US-20040053974-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | NQO2 3001/4885CA2 1808/4885MTNR1A 898/4885 |
| US-20050288339-A1 | Medicinal compositions containing diuretic and insulin resistance-improving agent | GPR119, INSR, IRS1 | NQO2 3001/4885CA2 1808/4885MTNR1A 898/4885 |
| US-20140086936-A1 | MATRIPTASE INHIBITORS AND USES THEREOF AGAINST ORTHOMYXOVIRIDAE INFECTIONS | MMP7, MATR3, ADAMTS1 | NQO2 4090/4885CA2 2453/4885MTNR1A 709/4885 |
| US-20030162808-A1 | Acetindine derivatives, their preparation and medicaments containing them | ADRA1D, ADRB2, AZI2 | NQO2 2141/4885CA2 515/4885MTNR1A 462/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.